#TalkingRegMed episode 6: Brexit with Matthew Durdy, Cell and Gene Therapy Catapult
In this episode of #TalkingRegMed, Matthew Durdy, Chief Business Officer, Cell and Gene Therapy Catapult, explains the effect of Brexit on cell therapy development in the UK.
Please sign in or register for FREE
Sign in to RegMedNet
Not yet a member? Become a member FREE to:
- Get unlimited access to ALL CONTENT
- Read selected articles from journals such as Regenerative Medicine FREE
- Receive a weekly email roundup of the latest news and expert opinions
Did you know?
Your RegMedNet account also gives you access to communities on drug discovery, real-world evidence and 3D printing in medicine. Find out more>>